TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.

S Barbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.